AVOID Phase III Trial showed a 5,2% reduction in anastomotic leak rates when ICG used for left-sided colectomy

Colorful surgery for better treatment and prevention of complications they said last weekend on national television. Green is already a scientific certainty as shown by the results of the AVOID trial.

Between July 2, 2020, and Feb 21, 2023, 982 patients were enrolled. After the exclusion of 51 patients, the intention-to-treat population comprised 931 (463 assigned Fluorescence Guided Bowel Anastomosis (FGBA) and 468 assigned conventional method) In patients who had left-sided
colorectal surgery, the 90-day anastomotic leakage rate was lower in the FGBA group (20 [8%] of 264) than in the conventional group (33 [13%] of 257.

Among the 521 patients who had left-sided surgery, the majority (440 [84%]) had rectosigmoid
resection (ie, sigmoidectomy, low anterior resection, and transanal total mesorectal excision).  this study provides evidence supporting the efficacy of ICG NIR fluorescence bowel perfusion assessment to prevent anastomotic leakage in patients undergoing minimally invasive left-sided and, specifically, rectosigmoid cancer resections. In alignment with current evidence, we recommend incorporating ICG NIR fluorescence imaging into surgical guidelines for patients undergoing rectosigmoid resections for cancer.

https://pubmed.ncbi.nlm.nih.gov/35365509/

 

 

Picture of John van Wezel

John van Wezel

Advies delen met anderen

Inhoud